Mediolanum International Funds Ltd Has $4.68 Million Position in United Therapeutics Corporation (NASDAQ:UTHR)

Key Points

• Mediolanum International Funds Ltd increased its stake in United Therapeutics Corporation by 192.2%, acquiring an additional 10,036 shares, bringing its total holdings to 15,257 shares valued at $4.68 million.
• Insider transactions included EVP Paul A. Mahon selling 11,000 shares, reducing his ownership by 23.02%, while Director Richard Giltner sold 3,036 shares, marking a 13.54% decrease in their stake.
• United Therapeutics' stock opened at $304.50 and has a market cap of $13.74 billion, with earnings per share reported at $6.63, exceeding analyst expectations.

Mediolanum International Funds Ltd increased its stake in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 192.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,257 shares of the biotechnology company's stock after purchasing an additional 10,036 shares during the quarter. Mediolanum International Funds Ltd's holdings in United Therapeutics were worth $4,683,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of UTHR. Allianz Asset Management GmbH lifted its holdings in shares of United Therapeutics by 96.9% during the 1st quarter. Allianz Asset Management GmbH now owns 67,576 shares of the biotechnology company's stock valued at $20,832,000 after buying an additional 33,254 shares during the last quarter. Cerity Partners LLC lifted its holdings in shares of United Therapeutics by 30.4% during the fourth quarter. Cerity Partners LLC now owns 11,588 shares of the biotechnology company's stock worth $4,098,000 after buying an additional 2,702 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of United Therapeutics by 11.4% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,678 shares of the biotechnology company's stock valued at $1,129,000 after purchasing an additional 376 shares during the period. Korea Investment CORP increased its position in shares of United Therapeutics by 6.2% during the fourth quarter. Korea Investment CORP now owns 39,289 shares of the biotechnology company's stock valued at $13,863,000 after purchasing an additional 2,300 shares during the period. Finally, Concurrent Investment Advisors LLC bought a new stake in shares of United Therapeutics during the first quarter valued at approximately $227,000. Hedge funds and other institutional investors own 94.08% of the company's stock.

Wall Street Analysts Forecast Growth

UTHR has been the topic of a number of analyst reports. JPMorgan Chase & Co. lowered their price target on United Therapeutics from $350.00 to $330.00 and set an "overweight" rating on the stock in a research report on Tuesday, July 8th. Morgan Stanley dropped their price objective on United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating for the company in a report on Thursday, July 10th. Wells Fargo & Company reissued an "equal weight" rating and set a $314.00 price target (down from $395.00) on shares of United Therapeutics in a research report on Friday, April 25th. Cantor Fitzgerald started coverage on United Therapeutics in a report on Monday, June 2nd. They issued an "overweight" rating and a $405.00 price target on the stock. Finally, Bank of America dropped their target price on United Therapeutics from $321.00 to $315.00 and set a "neutral" rating on the stock in a report on Wednesday, June 11th. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $383.08.

United Therapeutics Price Performance

NASDAQ:UTHR traded down $16.35 during trading hours on Wednesday, reaching $281.21. 580,394 shares of the company were exchanged, compared to its average volume of 491,853. The company has a market capitalization of $12.69 billion, a P/E ratio of 11.23, a P/E/G ratio of 6.50 and a beta of 0.53. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $417.82. The business has a 50 day moving average of $299.63 and a 200 day moving average of $314.91.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). The business had revenue of $798.60 million during the quarter, compared to analyst estimates of $802.13 million. United Therapeutics had a net margin of 40.44% and a return on equity of 19.33%. The company's revenue for the quarter was up 11.7% compared to the same quarter last year. During the same period in the prior year, the business posted $5.85 EPS. As a group, equities research analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Paul A. Mahon sold 11,000 shares of the company's stock in a transaction that occurred on Thursday, July 24th. The stock was sold at an average price of $304.11, for a total value of $3,345,210.00. Following the completion of the transaction, the executive vice president owned 36,781 shares of the company's stock, valued at $11,185,469.91. This represents a 23.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Nilda Mesa sold 645 shares of the business's stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $289.99, for a total transaction of $187,043.55. Following the completion of the sale, the director directly owned 4,883 shares in the company, valued at approximately $1,416,021.17. This represents a 11.67% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 81,681 shares of company stock worth $24,628,589. 10.30% of the stock is owned by company insiders.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.